HIV is infamous for its ability to hide in the human body for decades, typically requiring long-term treatment to prevent a ...

Tislelizumab addition to CRT improved survival in ESCC, with group B showing a 1-year PFS rate of 73% and OS rate of 85%. The trial's primary endpoint was PFS, with secondary endpoints including OS, ...

I was taken care of by my dad when she wasn’t around, and while he treated me well, we didn’t connect the same way that I did ...

Novel regimen GO-4, combining melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cells shows manageable adverse reactions and a strong signal of efficacy in patients with BRCA-relat ...

New gene-editing project targets thalassemia’s root cause A new research project at the Cyprus Institute of Neurology and ...

From the 2010s to the present, the existing technologies in the clinic and operating room have been improved with the goals ...

The new luxury for the ultra-high-net-worth individual is not a product but time, driving a trillion-dollar global wellness ...

Touted by longevity experts, celebrated by biohackers, and whispered about in elite wellness circles, NAD+ is the molecule at ...

Michael Ritchie, chief commercial officer at Champions Oncology, explains what makes radiopharmaceuticals unique in the treatment of cancer.

A study published in Science reveals a cellular mechanism involved in the inheritance of genetic mutations. The study also ...

Inspired by living cells, researchers have designed DNA molecules that allow drug concentrations in blood to be measured ...

EG110A received FDA fast track designation to treat neurogenic detrusor overactivity, a bladder issue common in MS.